Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)

University of Kansas

Status and phase

Active, not recruiting

Phase 2

Conditions

Lynch Syndrome

Colorectal Cancer

Treatments

Drug: Omega-3 fatty acid ethyl esters (2 gram)

Study type

Interventional

Funder types

Other

Identifiers

NCT03831698

IIT-2018-Omega3-CRC-Prev

Details and patient eligibility

About

This is a pilot study aimed at assessing the effects of moderate dose omega-3-acid ethyl esters capsules (generic Lovaza) on molecular, and intestinal microbiota changes in participants at high risk for colorectal cancer. The study will be a single arm, open label study.

Enrollment

21 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Ability of participant or Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
Candidate for elective endoscopy procedure
Participants with known Lynch Syndrome
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
Willing to undergo a colonoscopy and biopsy at baseline and another colonoscopy and biopsy at 12 months visit.
Participants taking Aspirin for chemoprevention must agree to stop it for at least 4 weeks prior to study entry and throughout the trial period
Adequate organ and marrow function
Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use two forms of adequate contraception (hormonal AND barrier method of birth control) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she should inform her treating physician immediately.
Men of child-bearing potential must not father a child or donate sperm while on this study and for 90 days after their last study treatment.

Exclusion criteria

Current or anticipated use of other investigational agents while participating in this study.
Psychiatric illness/social situations that could limit compliance with study requirements.
Pregnant or breast feeding.
Familial adenomatous polyposis, Putz-Jeghers disease, ulcerative colitis, or Crohn's disease.
Previous or known active malignancies, except non-melanoma skin cancers, unless curatively treated and with no evidence of recurrence for more than 5 years
Current use of anticoagulation therapy
Current use of therapeutic doses of aspirin for reasons other than chemoprevention
Use of omega 3 fatty acids or flaxseed supplements within 4 weeks before this study's screening/baseline colonoscopy
Use of high dose omega 3 fatty acids within the past 3 months prior to study baseline/screening
Current, regular use of non-steroidal anti-inflammatory drugs (NSAIDS)
Allergy to fish and/or fish products
Uncontrolled infectious disease
Malabsorption syndrome, disease affecting gastrointestinal function, or previous resection of the stomach or small bowel.
Unable to swallow and retain oral medication